Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis and Kenalog for Radiation Retinopathy
NCT00811200Phase 3Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2009
- Primary completion
- Jan 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Orthosteric Ligands
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab and triamcinolone acetonide in radiation retinopathy (RR) (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Best Corrected Visual Acuity at 1 year. Status: unknown.
02
Drugs
ranibizumabtriamcinolone acetonide
03
Conditions
radiation retinopathy (RR)
Beyond the preview
Go deeper on NCT00811200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811200.